Military motion-assisted memory desensitization and reconsolidation for treatment resistant post traumatic stress disorder in military veterans

Phase II randomised controlled trial of military motion-assisted memory desensitization and reconsolidation for treatment resistant post traumatic stress disorder in military veterans

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN80028105

Enrollment

Registered

2017-02-23

Start date

2017-04-01

Completion date

Unknown

Last updated

2022-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment-resistant post traumatic stress disorder Mental and Behavioural Disorders Post-traumatic stress disorder

Interventions

An experienced researcher blind to randomisation will conduct all assessments. The initial assessment will ensure that the inclusion criteria are satisfied. Demographic and other background data will

those who continue to fulfil the inclusion criteria will be randomised (computer generated via a trials unit) to one of the two groups: 1. The 3MDR therapy delivered weekly over nine w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 or over 2. Informed consent 3. Meet DSM529 criteria for combat-related PTSD 4. Treatment resistance, defined as prior receipt of a trauma focused psychological treatment without loss of PTSD diagnosis

Exclusion criteria

Exclusion criteria: 1. Psychosis 2. DSM5 severe major depressive episode 3. Substance dependence 4. Change in psychotropic medication within 1 month 5. Suicidal intent 6. Inability to walk at a normal pace for 30-45 minutes on a treadmill

Design outcomes

Primary

Measure	Time frame
Symptoms of PTSD, measured using the Clinician Administered PTSD Scale for DSM5 (CAPS5) at baseline, 12 and 26 weeks	—

Secondary

Measure	Time frame
1. Traumatic stress, measured using the Impact of Event Scale – revised 2. Quality of life/functional impairment, measured using the Work and Social Adjustment Scale 3. Depression, measured using the Patient Health Questionnaire-9 (PHQ-9) 4. Anxiety, measured using General Anxiety Disorder-7 (GAD-7) 5. Alcohol use, measured using AUDIT-O36 6. Changes in sleep, measured using the insomnia severity index (ISI) 7. Perceived social support, measured using the Multidimensional Scale for Perceived Social Support 8. Health-related quality of life, measured using the EQ5D-5L All measured at baseline, 12 and 26 weeks	—

Measure

Time frame

1. Traumatic stress, measured using the Impact of Event Scale – revised 2. Quality of life/functional impairment, measured using the Work and Social Adjustment Scale 3. Depression, measured using the Patient Health Questionnaire-9 (PHQ-9) 4. Anxiety, measured using General Anxiety Disorder-7 (GAD-7) 5. Alcohol use, measured using AUDIT-O36 6. Changes in sleep, measured using the insomnia severity index (ISI) 7. Perceived social support, measured using the Multidimensional Scale for Perceived Social Support 8. Health-related quality of life, measured using the EQ5D-5L All measured at baseline, 12 and 26 weeks

—

Countries

United Kingdom, Wales

Contacts

Public ContactKali Barawi

barawik1@cf.ac.uk+44 (0)292 068 8321

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026